PFIZER INC (PFE)
Pfizer Inc. (NYSE: PFE) is an American pharmaceutical company headquartered in New York City. It develops, manufactures, and commercializes medicines and vaccines across areas including oncology, immunology, cardiology, infectious diseases, and rare diseases. Its key products include Eliquis (co-marketed with Bristol Myers Squibb), Prevnar, Paxlovid, and the Abrysvo vaccine.
| Ticker | PFE |
|---|
| Company | PFIZER INC |
|---|
| Exchange | NYSE |
|---|
| Headquarters | NEW YORK, NY |
|---|
Income statement — period ending 2026-06-28
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$263,000,000 |
|---|
| Cost of Goods and Services Sold | $4,092,000,000 |
|---|
| Earnings Per Share, Basic | 0 USD/shares |
|---|
| Earnings Per Share, Diluted | 0 USD/shares |
|---|
| Gross Profit (derived) | $10,942,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | -$653,000,000 |
|---|
| Income Tax Expense (Benefit) | -$407,000,000 |
|---|
| Interest Expense | $667,000,000 |
|---|
| Investment Income, Interest | $113,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | -$248,000,000 |
|---|
| Net Income (Loss) Attributable to Noncontrolling Interest | $10,000,000 |
|---|
| Net Income (Loss) Available to Common Stockholders, Basic | -$248,000,000 |
|---|
| Other Nonoperating Income (Expense) | -$3,716,000,000 |
|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | -$237,000,000 |
|---|
| Restructuring Charges | $419,000,000 |
|---|
| Revenues | $15,034,000,000 |
|---|
| Selling, General and Administrative Expense | $3,411,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $521,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 5,699,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 5,699,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro